Company Analysis WuXi Biologics (Cayman) Inc.
1. Summary
Advantages
- Price (6.11 $) is less than fair price (8.37 $)
- The stock's return over the last year (93.45%) is higher than the sector average (0.5232%).
- Current debt level 4.07% is below 100% and has decreased over 5 years from 10.95%.
Disadvantages
- Dividends (0%) are below the sector average (5.68%).
- The company's current efficiency (ROE=8.43%) is lower than the sector average (ROE=38.2%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| WuXi Biologics (Cayman) Inc. | Technology | Index | |
|---|---|---|---|
| 7 days | 0.4% | -2.8% | 1.1% |
| 90 days | 4.3% | -4.2% | 9.1% |
| 1 year | 93.4% | 0.5% | 12.4% |
WXXWY vs Sector: WuXi Biologics (Cayman) Inc. has outperformed the "Technology" sector by 92.93% over the past year.
WXXWY vs Market: WuXi Biologics (Cayman) Inc. has outperformed the market by 81.1% over the past year.
Stable price: WXXWY is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: WXXWY with weekly volatility of 1.8% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (6.11 $) is lower than the fair price (8.37 $).
Price significantly below the fair price: The current price (6.11 $) is 37% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (63.17) is lower than that of the sector as a whole (217.76).
P/E vs Market: The company's P/E (63.17) is higher than that of the market as a whole (59.99).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.88) is lower than that of the sector as a whole (5.45).
P/BV vs Market: The company's P/BV (4.88) is higher than that of the market as a whole (3.41).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (12.61) is higher than that of the sector as a whole (5.76).
P/S vs Market: The company's P/S indicator (12.61) is higher than that of the market as a whole (3.65).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (36.75) is higher than that of the sector as a whole (14.53).
EV/Ebitda vs Market: The company's EV/Ebitda (36.75) is lower than that of the market as a whole (40.09).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 20.26% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (20.26%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.19%).
5.4. ROE
ROE vs Sector: The company's ROE (8.43%) is lower than that of the sector as a whole (38.2%).
ROE vs Market: The company's ROE (8.43%) is lower than that of the market as a whole (41.13%).
5.5. ROA
ROA vs Sector: The company's ROA (6.01%) is lower than that of the sector as a whole (20.64%).
ROA vs Market: The company's ROA (6.01%) is lower than that of the market as a whole (29.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (11.15%) is lower than that of the sector as a whole (13.96%).
ROIC vs Market: The company's ROIC (11.15%) is higher than that of the market as a whole (11.01%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '5.68%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
